Predicting success in cancer prevention trials.
Vourlekis
Jason S
JS
Szabo
Eva
E
D000077556:Alitretinoin; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control; D011237:Predictive Value of Tests; D018168:Receptors, Retinoic Acid / Q000187:drug effects* / Q000378:metabolism; D012907:Smoking / Q000009:adverse effects / Q000378:metabolism*; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage / Q000494:pharmacology*; D024502:alpha-Tocopherol / Q000494:pharmacology
D000970:Antineoplastic Agents; D000975:Antioxidants; D014408:Biomarkers, Tumor; D018168:Receptors, Retinoic Acid; C082925:retinoic acid receptor beta; D000077556:Alitretinoin; D014212:Tretinoin; D024502:alpha-Tocopherol